MIRA Pharmaceuticals, Inc.

NASDAQ: MIRA · Healthcare · Drug Manufacturers - General

PublicHQ Baltimore, MD · Baltimore (Independent City)CIK 0001904286Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 56DQ —GM —SS 22

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ workforce scale, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$10.4M

Employees

as of 2026-09-18

Market cap

$31.9M

as of 2026-09-18

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$10.4M-$10.4M2025

Total assets$11.1M$11.1M2025

Liabilities$702.1k$702.1k2025

Equity$10.4M$10.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is MIRA Pharmaceuticals, Inc.’s financial profile?

MIRA Pharmaceuticals, Inc. earned -$10.4M in FY2025 net income.

Peers · Healthcare

Context Therapeutics Inc.——Sernova Corp.——Tevogen Bio Holdings Inc.——NurExone Biologic Inc.——Cell Source, Inc.——Vicapsys Life Sciences, Inc.——

Neighbors

Baltimore (Independent City) →

Constellation Energy Corporation$22.7B52D T. Rowe Price Group, Inc.$7.3B79B+Under Armour, Inc.$5.0B47D Rand Worldwide, Inc.$178.8M——BV Financial, Inc.——Medifast, Inc.$385.8M52D

Key facts

CEOErez Aminov

SectorHealthcare

IndustryDrug Manufacturers - General

HeadquartersBaltimore, MD

ExchangeNASDAQ: MIRA

Employees2

IPO date2023-08-14

Latest filings

8-K2026-09-17 8-K2026-09-16 8-K2026-09-01 10-Q2026-08-12 8-K2026-08-06 8-K2026-07-31 DEF 14A2026-07-28 8-K2026-07-10

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.